Immunovia Targeting Long-Term Market Penetration of 30% for IMMray™ PanCan-d
LUND, SWEDEN – Immunovia AB (publ) (“Immunovia”) today announced the company’s long-term market penetration target of 30% for IMMray™ PanCan-d, after reimbursement and widespread insurance coverage is achieved. As previously announced, Immunovia recently secured one of the largest funding raises for an EU-based diagnostics company, providing a strong financial position ahead of the company’s first product launch based on the IMMray™ platform. Immunovia’s first to market product IMMray™[ ]PanCan-d, is a long-sought solution for the unmet need of early and accurate detection of